{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:45:08Z","timestamp":1777351508173,"version":"3.51.4"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jss.2025.01.025","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:54:14Z","timestamp":1740981254000},"page":"157-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Contemporary Management of Malignant Ascites"],"prefix":"10.1016","volume":"307","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-1349","authenticated-orcid":false,"given":"Mason A.","family":"Vierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan B.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Bhutiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver S.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2025.01.025_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0885-3924(98)00037-2","article-title":"A survey of practice in management of malignant ascites","volume":"16","author":"Lee","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jss.2025.01.025_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/archinte.1979.03630390087029","article-title":"Abdominal paracentesis for malignant ascites","volume":"139","author":"Fischer","year":"1979","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jss.2025.01.025_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/clon.2002.0135","article-title":"The current and future management of malignant ascites","volume":"15","author":"Smith","year":"2003","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","article-title":"Malignant ascites: past, present, and future","volume":"198","author":"Adam","year":"2004","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jss.2025.01.025_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00270-005-0252-4","article-title":"Percutaneous placement of peritoneal port-catheter in patients with malignant ascites","volume":"30","author":"Ozkan","year":"2007","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.jss.2025.01.025_bib7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/jpm.2013.0427","article-title":"Safety and efficacy of the PleurX catheter for the treatment of malignant ascites","volume":"17","author":"Narayanan","year":"2014","journal-title":"J Palliat Med"},{"key":"10.1016\/j.jss.2025.01.025_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jpainsymman.2008.09.008","article-title":"Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review","volume":"38","author":"Fleming","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jss.2025.01.025_bib9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/0016-5085(92)91520-E","article-title":"Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics","volume":"103","author":"Pockros","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jss.2025.01.025_bib10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/00000658-197410000-00023","article-title":"Peritoneo-venous shunting for ascites","volume":"180","author":"Leveen","year":"1974","journal-title":"Ann Surg"},{"key":"10.1016\/j.jss.2025.01.025_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/1097-0142(19820915)50:6<1204::AID-CNCR2820500631>3.0.CO;2-W","article-title":"Selection of patients with malignant ascites for a peritoneovenous shunt","volume":"50","author":"Cheung","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"De Bree","year":"2017","journal-title":"Pleura and Peritoneum"},{"key":"10.1016\/j.jss.2025.01.025_bib13","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1200\/JCO.1990.8.12.2054","article-title":"Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer","volume":"8","author":"Schilsky","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00001813-199406000-00007","article-title":"Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin","volume":"5","author":"Maiche","year":"1994","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jss.2025.01.025_bib15","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonzalez-Moreno","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021546","article-title":"Cytoreductive surgery and HIPEC for malignant ascites from colorectal cancer - a randomized study","volume":"99","author":"Ba","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jss.2025.01.025_bib18","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1245\/s10434-013-3224-y","article-title":"Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites","volume":"21","author":"Randle","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib19","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1245\/s10434-011-1793-1","article-title":"Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin","volume":"18","author":"Hill","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib20","first-page":"137","article-title":"Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy","volume":"63","author":"Loggie","year":"1997","journal-title":"Am Surg"},{"key":"10.1016\/j.jss.2025.01.025_bib21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/BF01675656","article-title":"Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination","volume":"15","author":"Yonemura","year":"1991","journal-title":"World J Surg"},{"key":"10.1016\/j.jss.2025.01.025_bib22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00432-014-1692-5","article-title":"Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites","volume":"140","author":"Ba","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib23","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3892\/or.2012.1913","article-title":"B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites","volume":"28","author":"Cui","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jss.2025.01.025_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejso.2007.05.015","article-title":"Laparoscopic\u00a0hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary\u00a0to\u00a0unresectable peritoneal carcinomatosis from advanced gastric cancer","volume":"34","author":"Facchiano","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","article-title":"Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients","volume":"100","author":"Valle","year":"2009","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijsu.2015.09.074","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery","volume":"23","author":"Valle","year":"2015","journal-title":"Int J Surg"},{"key":"10.1016\/j.jss.2025.01.025_bib27","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00464-013-2800-3","article-title":"Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites","volume":"27","author":"Ba","year":"2013","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jss.2025.01.025_bib28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ejso.2006.03.014","article-title":"Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites","volume":"32","author":"Garofalo","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cgt.2016.49","article-title":"Intraperitoneal immunotherapy: historical perspectives and modern therapy","volume":"23","author":"Morano","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jss.2025.01.025_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102646","article-title":"Malignant ascites: current therapy options and treatment prospects","volume":"121","author":"Berger","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jss.2025.01.025_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","article-title":"Markedly elevated levels of vascular endothelial growth factor in malignant ascites","volume":"6","author":"Zebrowski","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7","article-title":"Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease","volume":"85","author":"Kraft","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2008.04.028","article-title":"Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer","volume":"111","author":"Hamilton","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2008.07.015","article-title":"The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report","volume":"111","author":"Kesterson","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10637-009-9351-4","article-title":"Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review","volume":"28","author":"Bellati","year":"2010","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.jss.2025.01.025_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib37","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1111\/jog.14112","article-title":"The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer","volume":"45","author":"Shimizu","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.jss.2025.01.025_bib38","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1200\/jco.2007.25.18_suppl.9043","article-title":"Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites","volume":"25","author":"El-Shami","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","article-title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Gotlieb","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2011.11.021","article-title":"A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites","volume":"125","author":"Colombo","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2016.05.004","article-title":"Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108","volume":"63","author":"Jordan","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2021.02.002","article-title":"Rezolve (ANZGOG-1101): a phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","volume":"161","author":"Sjoquist","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520986664","article-title":"Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites","volume":"49","author":"Kou","year":"2021","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jss.2025.01.025_bib40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00000421-198204000-00064","article-title":"Human leukocyte interferon therapy for advanced ovarian carcinoma","volume":"5","author":"Einhorn","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0090-8258(90)90284-R","article-title":"A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer","volume":"40","author":"Berek","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib47","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/1097-0142(19930315)71:6<2027::AID-CNCR2820710617>3.0.CO;2-C","article-title":"Intraperitoneal interferon in the management of malignant ascites","volume":"71","author":"Stuart","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/0277-5379(91)90024-8","article-title":"Treatment of malignant ascites due to recurrent\/refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy in\u00a0vivo and in\u00a0vitro","volume":"27","author":"Bezwoda","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib49","first-page":"579","article-title":"Intracavitary beta-interferon for the management of pleural and\/or abdominal effusions in patients with advanced cancer refractory to chemotherapy","volume":"5","author":"Gebbia","year":"1991","journal-title":"In\u00a0Vivo (Athens)"},{"key":"10.1016\/j.jss.2025.01.025_bib50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000055374","article-title":"Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study","volume":"61","author":"Sartori","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.jss.2025.01.025_bib51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jir.1996.16.403","article-title":"Tumor necrosis factor effects on ascites formation in an experimental tumor model","volume":"16","author":"Behammer","year":"1996","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jss.2025.01.025_bib52","first-page":"2986","article-title":"Phase I study of recombinant tumor necrosis factor in cancer patients","volume":"47","author":"Blick","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2025.01.025_bib53","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1055\/s-2008-1026344","article-title":"[Therapy of ascites with tumor necrosis factor in ovarian cancer]","volume":"50","author":"Kaufmann","year":"1990","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.jss.2025.01.025_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0277-5379(91)90467-R","article-title":"Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites","volume":"27","author":"Rath","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/gyno.1996.4529","article-title":"A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma","volume":"64","author":"Hirte","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib56","first-page":"577","article-title":"Prospective, multi-center clinical study of rmhTNF-NC injection in the treatment of Chinese malignant pleural effusion or perioneal effusion patients","volume":"21","author":"Qin","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031883","article-title":"A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers","volume":"101","author":"Wu","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jss.2025.01.025_bib59","first-page":"9","article-title":"Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209)","volume":"56","author":"Tsukagoshi","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.jss.2025.01.025_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.2910310102","article-title":"Intrapleural administration of OK432 in cancer patients: activation of NK cells and reduction of suppressor cells","volume":"31","author":"Uchida","year":"1983","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib61","first-page":"357","article-title":"New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival","volume":"93","author":"Torisu","year":"1983","journal-title":"Surgery"},{"key":"10.1016\/j.jss.2025.01.025_bib62","first-page":"365","article-title":"New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction","volume":"93","author":"Katano","year":"1983","journal-title":"Surgery"},{"key":"10.1016\/j.jss.2025.01.025_bib63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02469915","article-title":"Effects of intraperitoneal administration of OK-432 for patients with advanced cancer","volume":"15","author":"Toge","year":"1985","journal-title":"The Jpn J Surg"},{"key":"10.1016\/j.jss.2025.01.025_bib64","first-page":"2201","article-title":"Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients","volume":"15","author":"Yamaguchi","year":"1995","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jss.2025.01.025_bib65","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.bjc.6601379","article-title":"Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus Interleukin-2","volume":"89","author":"Yamaguchi","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib66","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bjc.6690421","article-title":"Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion","volume":"80","author":"Nio","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib67","first-page":"3917","article-title":"The past, the present and future of the OK-432 therapy for patients with malignant effusions","volume":"18","author":"Katano","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jss.2025.01.025_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11864-008-0068-y","article-title":"Treatment of malignant ascites","volume":"9","author":"Chung","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00262-014-1566-3","article-title":"Phase II clinical trial of ex\u00a0vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer","volume":"63","author":"Chung","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jss.2025.01.025_bib70","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/1752-1947-2-372","article-title":"Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report","volume":"2","author":"Kimura","year":"2008","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jss.2025.01.025_bib71","first-page":"4272","article-title":"The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites","volume":"7","author":"Ai","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.jss.2025.01.025_bib72","first-page":"3940","article-title":"Clinical efficacy of intra-cavitary infusions of autologous dendritic cell\/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites","volume":"12","author":"He","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jss.2025.01.025_bib73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cam4.196","article-title":"Intraperitoneal injection of in\u00a0vitro expanded V\u03b39V\u03b42 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer","volume":"3","author":"Wada","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.jss.2025.01.025_bib74","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(82)90046-0","article-title":"Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours","volume":"2","author":"Epenetos","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2025.01.025_bib75","first-page":"4719","article-title":"Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration","volume":"47","author":"Ward","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2025.01.025_bib77","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bjc.1988.280","article-title":"The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy","volume":"58","author":"Ward","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0090-8258(92)90084-V","article-title":"Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3","volume":"47","author":"Buckman","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib80","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ijc.21165","article-title":"Immunotherapy of malignant ascites with trifunctional antibodies","volume":"117","author":"Heiss","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib81","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000324667","article-title":"Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I\/II trial","volume":"34","author":"Str\u00f6hlein","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.jss.2025.01.025_bib85","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","article-title":"Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study","volume":"24","author":"Berek","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib86","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12032-014-0076-7","article-title":"Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study","volume":"31","author":"Sehouli","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib84","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1634\/theoncologist.2015-0076","article-title":"Outpatient intraperitoneal catumaxomab therapy for malignant ascites related to advanced gynecologic neoplasms","volume":"20","author":"Kurbacher","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jss.2025.01.025_bib87","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bjc.2014.443","article-title":"Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study","volume":"111","author":"Sehouli","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ijc.10562","article-title":"Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma","volume":"101","author":"Marm\u00e9","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib89","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2021.01.045","article-title":"Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites","volume":"148","author":"Wang","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib91","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0090-8258(89)90169-8","article-title":"Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer","volume":"34","author":"Finkler","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib76","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1200\/JCO.1987.5.12.1890","article-title":"Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies","volume":"5","author":"Epenetos","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib78","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/mabs.1.6.10015","article-title":"Bispecific antibodies for cancer therapy: the light at the end of the tunnel?","volume":"1","author":"Chames","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.jss.2025.01.025_bib79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","article-title":"Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers","volume":"94","author":"Went","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2025.01.025_bib82","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2025.01.025_bib92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2007.06.155","article-title":"Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR\/Flk-1 of endothelial cells","volume":"361","author":"Ling","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jss.2025.01.025_bib93","first-page":"283","article-title":"[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]","volume":"8","author":"Wang","year":"2005","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.jss.2025.01.025_bib95","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2217\/fon-2021-0896","article-title":"Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites","volume":"18","author":"Zhan","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib94","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.7314\/APJCP.2015.16.18.8637","article-title":"Intraperitoneal perfusion therapy of endostar combined with platinum chemotherapy for malignant serous effusions: a meta-analysis","volume":"16","author":"Liang","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jss.2025.01.025_bib96","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/08968608231205851","article-title":"Weekly intraperitoneal steroid infusion to treat recurrent ascites in a patient with early stage of peritoneal dialysis-related encapsulating peritoneal sclerosis: a case report","volume":"44","author":"Chen","year":"2024","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.jss.2025.01.025_bib97","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0885-3924(00)00106-8","article-title":"A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites","volume":"19","author":"Mackey","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jss.2025.01.025_bib98","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2008.07.002","article-title":"The use of intraperitoneal triamcinolone acetonide for the management of recurrent malignant ascites in a patient with non-Hodgkin's lymphoma","volume":"36","author":"Jenkin","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jss.2025.01.025_bib99","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2025.01.025_bib100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jss.2025.01.025_bib101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: characterization of clinical efficacy and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol Ther - Oncolytics"},{"key":"10.1016\/j.jss.2025.01.025_bib102","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.3390\/cancers13194873","article-title":"Effectiveness of cell-free and concentrated ascites reinfusion therapy in the treatment of malignancy-related ascites: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jss.2025.01.025_bib103","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/jgh.15620","article-title":"Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites","volume":"36","author":"Ito","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jss.2025.01.025_bib104","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ejso.2015.04.013","article-title":"Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1","volume":"41","author":"Yamaguchi","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-021-02077-6","article-title":"Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)","volume":"27","author":"Matsusaki","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib106","article-title":"Evaluation of efficacy and safety for compound kushen injection combined with intraperitoneal chemotherapy for patients with malignant ascites: a systematic review and meta-analysis","volume":"14","author":"Yu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jss.2025.01.025_bib107","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1191\/026921699677473561","article-title":"Octreotide as an agent for the relief of malignant ascites in palliative care patients","volume":"13","author":"Cairns","year":"1999","journal-title":"Palliat Med"},{"key":"10.1016\/j.jss.2025.01.025_bib108","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clon.2004.06.016","article-title":"The successful treatment of chylous effusions in malignant disease with octreotide","volume":"17","author":"Mincher","year":"2005","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000337246","article-title":"A pilot study of long-acting octreotide for symptomatic malignant ascites","volume":"82","author":"Jatoi","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.jss.2025.01.025_bib111","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1756283X16684688","article-title":"Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites","volume":"10","author":"Stirnimann","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jss.2025.01.025_bib112","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41395-018-0100-1","article-title":"Treatment of malignant ascites using an automated pump device","volume":"113","author":"Storni","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jss.2025.01.025_bib113","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12904-019-0497-3","article-title":"Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites","volume":"18","author":"Fotopoulou","year":"2019","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.jss.2025.01.025_bib114","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejso.2019.10.033","article-title":"A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study","volume":"47","author":"Valle","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2025.01.025_bib115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/COC.0000000000000878","article-title":"Celecoxib and myrtol: a novel therapy for recurrent appendiceal mucinous neoplasms with extensive peritoneal dissemination","volume":"45","author":"Vierra","year":"2022","journal-title":"Am J Clin Oncol"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480425000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480425000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:21:09Z","timestamp":1777350069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480425000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":114,"alternative-id":["S0022480425000447"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2025.01.025","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Management of Malignant Ascites","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2025.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}